Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Foresite Capital Management V, LLC (CIK 1792206) reported $362.2M across 9 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: ALMS ($165.9M, 45.81%), CGON ($76.7M, 21.17%), IRON ($27.4M, 7.55%), HIMS ($25.6M, 7.07%), PHVS ($23.0M, 6.34%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | ALMS | ALUMIS INC. | $165.9M | 45.81% | 5.9M | Hold |
| 2 | CGON | CG Oncology, Inc. | $76.7M | 21.17% | 1.1M | Added |
| 3 | IRON | Disc Medicine, Inc. | $27.4M | 7.55% | 374,069 | Hold |
| 4 | HIMS | Hims & Hers Health, Inc. | $25.6M | 7.07% | 738,151 | Hold |
| 5 | PHVS | Pharvaris N.V. | $23.0M | 6.34% | 664,142 | Added |
| 6 | EIKN | Eikon Therapeutics, Inc. | $17.2M | 4.75% | 1.3M | Hold |
| 7 | ODTX | Odyssey Therapeutics, Inc. | $13.3M | 3.68% | 713,105 | New |
| 8 | LYEL | Lyell Immunopharma, Inc. | $6.7M | 1.85% | 476,386 | Trimmed |
| 9 | NRIX | Nurix Therapeutics, Inc. | $6.4M | 1.77% | 265,000 | Hold |
| 10 | MAZE | Maze Therapeutics, Inc. | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-06-30